Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Press release - No. 10 / 2018
Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam
Copenhagen, April 12, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the Kempen Life Science Conference in Amsterdam on April 18, 2018.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
